Nanoparticles and the lung: friend or foe?
Nanomedicine is a rapidly evolving field with high potential for developing novel research, diagnosis, and/or therapeutic approaches for lung diseases. However, for engineered nanomaterials to reach their true potential, there are still a number of unanswered questions regarding nanomaterial vs. tissue properties that dictate lung cellular uptake, distribution, and intracellular effects, and particle vs. tissue factors that determine toxicity vs. beneficial effects in the lung. Some of these key questions are highlighted in this Perspectives. Addressing these important issues will help improve nanoparticle design and enhance enthusiasm for more widespread use of nanotechnology in pulmonary medicine.
Dept. of Anesthesiology, Mayo Clinic, Rochester, MN 55905. prakash.ys@mayo.edu.
Y S
YS
Prakash
Sadis
S
Matalon
D006801:Humans; D008168:Lung / Q000276:immunology / Q000502:physiology; D008171:Lung Diseases / Q000276:immunology / Q000503:physiopathology / Q000628:therapy*; D053758:Nanoparticles / Q000009:adverse effects* / Q000627:therapeutic use*; D015272:Pulmonary Medicine / Q000639:trends*